AUS
NZ
UK
CA
USA
IND
Highlights
- Fisher & Paykel Healthcare has posted a stronger full-year result led by hospital hardware demand.
- United States respiratory-care sales underpinned the lift, even against tariff and currency headwinds.
- A higher full-year dividend kept the med-tech name in focus among mid-cap health stories.
Respiratory and hospital-care device maker Fisher & Paykel Healthcare (ASX:FPH) is drawing attention after a stronger full-year result showed its hospital hardware business firing, particularly across the United States. The trans-Tasman group, a familiar mid-cap name straddling the Australian and New Zealand markets, lifted revenue and earnings over the year and raised its dividend, keeping it near the front of the conversation about resilient health-technology stories despite a backdrop of tariffs and swinging currencies.
Hospital hardware leads the way
The standout in the latest result was the hospital division, where sales of respiratory humidification hardware and consumables grew, helped by rising use of the group's devices in United States wards. Fisher & Paykel Healthcare has spent years placing its breathing-support systems into hospitals, and that installed base drives a long tail of consumable sales. Higher hardware placements today tend to seed recurring consumable demand well into the future, a model the company leans on heavily.
Growth against real headwinds
The improvement came despite genuine pressures. United States tariffs and foreign-exchange movements weighed on margins, and management flagged that both remain worth watching in coming periods. Even so, revenue and net profit both advanced over the year, and the board lifted the total dividend meaningfully, signalling confidence in the underlying cash generation of the business even as external costs bite.
That combination of steady growth and reliable payouts has kept the company firmly inside the ASX 200 and made it a fixture among mid-cap health names that offer exposure to structural demand for medical care rather than the swings of the commodity cycle.
A dual-listed med-tech
Fisher & Paykel Healthcare trades on both sides of the Tasman and reports in New Zealand dollars, which adds a currency layer for those following the Australian line. Its two engines, hospital hardware and the homecare business built around sleep-apnoea and respiratory support, give it a spread across acute and chronic care. Manufacturing across multiple countries also shapes how tariffs and exchange rates feed through to the bottom line.
Where it sits among mid-cap health names
For anyone mapping the local health-technology field, the company regularly features in discussions about defensive ASX Midcap Stocks with global reach. Its blend of recurring consumable revenue, an entrenched hospital presence and steady dividends sets it apart from earlier-stage device hopefuls, though the premium the market attaches to that quality means margins and tariff impacts will stay under the microscope.
What to watch next
From here, focus falls on how tariffs and currency shifts flow through to future margins, the pace of new hardware placements in key markets, and momentum in the homecare range. Continued strength in the hospital installed base would reinforce the durable, consumables-led story that has long defined the group.
